Differential response rates in early-phase cancer clinical trials (EPCCT).

Rozana Abdul Rahman,Neethu Billy Graham Mariam,Hitesh Mistry,Sreeja Aruketty,Matt Church,Aidi Adamson-Raieste,Julie-Anne Scott,Fiona C. Thistlethwaite,Matthew G Krebs,Louise Carter,Donna M. Graham,Natalie Cook

Differential response rates in early-phase cancer clinical trials (EPCCT).

2021

Rozana Abdul Rahman
Neethu Billy Graham Mariam
Hitesh Mistry
Sreeja Aruketty
Matt Church
Aidi Adamson-Raieste
Julie-Anne Scott
Fiona C. Thistlethwaite
Matthew G Krebs
Louise Carter
Donna M. Graham
Natalie Cook

3133Background: The primary objective of EPCCT (phase I and non-randomised phase II trials) is to determine the safety and tolerability of new therapeutic agents. Response rates (RR) in these trial...

Keywords:

Tolerability
cancer clinical trial
Medicine
Internal medicine
Oncology
early phase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations